Market Cap 20.38B
Revenue (ttm) 9.87B
Net Income (ttm) 871.00M
EPS (ttm) N/A
PE Ratio 18.75
Forward PE 18.49
Profit Margin 8.82%
Debt to Equity Ratio 0.78
Volume 867,000
Avg Vol 888,926
Day's Range N/A - N/A
Shares Out 111.24M
Stochastic %K 15%
Beta 0.56
Analysts Sell
Price Target $195.18

Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 973 520 2700
Address:
500 Plaza Drive, Secaucus, United States
Bazzzigar
Bazzzigar Oct. 24 at 10:59 PM
$DGX hold long term
0 · Reply
Bazzzigar
Bazzzigar Oct. 24 at 6:23 PM
$DGX few more
0 · Reply
Small_time_trader
Small_time_trader Oct. 22 at 7:36 PM
$DGX Don’t sweat PAMA If PAMA is not delayed, many smaller labs instantly would be non - profitable and close their doors, big commercial labs like DGX would swoop in and grab the work. most likely Pama will continue to be pushed out until substantial changes are made to the pieces impacting laboratory medicine. Either way DGX wins
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 4:59 PM
Barclays has adjusted their stance on Quest Diagnostics ( $DGX ), setting the rating to Equal-Weight with a target price of 190 → 195.
0 · Reply
Bazzzigar
Bazzzigar Oct. 22 at 3:13 PM
$DGX sector up
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 2:09 PM
Truist Securities updates rating for Quest Diagnostics ( $DGX ) to Hold, target set at 195 → 205.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:57 PM
Leerink Partners has updated their rating for Quest Diagnostics ( $DGX ) to Outperform with a price target of 210.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:39 PM
Jefferies updates rating for Quest Diagnostics ( $DGX ) to Buy, target set at 200 → 215.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:37 PM
Jefferies has updated their rating for Quest Diagnostics ( $DGX ) to Buy with a price target of 200.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 7:46 PM
$DGX Share Price: $184.70 Contract Selected: Feb 20, 2026 $185 Calls Buy Zone: $7.48 – $9.24 Target Zone: $13.89 – $16.98 Potential Upside: 75% ROI Time to Expiration: 121 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on DGX
Quest Diagnostics: Investing In Healthcare's Future Today

Oct 6, 2025, 12:49 AM EDT - 19 days ago

Quest Diagnostics: Investing In Healthcare's Future Today


Quest Diagnostics Declares Quarterly Cash Dividend

Aug 13, 2025, 6:35 PM EDT - 2 months ago

Quest Diagnostics Declares Quarterly Cash Dividend


Quest Diagnostics Introduces Testing for Oropouche Virus

Jul 15, 2025, 7:57 AM EDT - 3 months ago

Quest Diagnostics Introduces Testing for Oropouche Virus


Quest Diagnostics Releases 2024 Corporate Responsibility Report

Jun 25, 2025, 9:07 AM EDT - 4 months ago

Quest Diagnostics Releases 2024 Corporate Responsibility Report


Quest Diagnostics: A Leader But Waiting For Better Price

May 3, 2025, 4:26 AM EDT - 6 months ago

Quest Diagnostics: A Leader But Waiting For Better Price


8 Upcoming Dividend Increases During Volatile Times

Apr 4, 2025, 1:43 PM EDT - 7 months ago

8 Upcoming Dividend Increases During Volatile Times

AMT BKU GD KAI ORCL REIT RNP


Bazzzigar
Bazzzigar Oct. 24 at 10:59 PM
$DGX hold long term
0 · Reply
Bazzzigar
Bazzzigar Oct. 24 at 6:23 PM
$DGX few more
0 · Reply
Small_time_trader
Small_time_trader Oct. 22 at 7:36 PM
$DGX Don’t sweat PAMA If PAMA is not delayed, many smaller labs instantly would be non - profitable and close their doors, big commercial labs like DGX would swoop in and grab the work. most likely Pama will continue to be pushed out until substantial changes are made to the pieces impacting laboratory medicine. Either way DGX wins
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 4:59 PM
Barclays has adjusted their stance on Quest Diagnostics ( $DGX ), setting the rating to Equal-Weight with a target price of 190 → 195.
0 · Reply
Bazzzigar
Bazzzigar Oct. 22 at 3:13 PM
$DGX sector up
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 2:09 PM
Truist Securities updates rating for Quest Diagnostics ( $DGX ) to Hold, target set at 195 → 205.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:57 PM
Leerink Partners has updated their rating for Quest Diagnostics ( $DGX ) to Outperform with a price target of 210.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:39 PM
Jefferies updates rating for Quest Diagnostics ( $DGX ) to Buy, target set at 200 → 215.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:37 PM
Jefferies has updated their rating for Quest Diagnostics ( $DGX ) to Buy with a price target of 200.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 7:46 PM
$DGX Share Price: $184.70 Contract Selected: Feb 20, 2026 $185 Calls Buy Zone: $7.48 – $9.24 Target Zone: $13.89 – $16.98 Potential Upside: 75% ROI Time to Expiration: 121 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Small_time_trader
Small_time_trader Oct. 21 at 4:37 PM
$DGX Folks this was a good ole fashioned beat and raise with up beat messaging and feel. This dip in price IS A GIFT Expect it to go higher all day and quickly get back to 190 price
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 4:23 PM
0 · Reply
induscapital
induscapital Oct. 21 at 2:18 PM
$LH $DGX If DGX is any cue then LH is going down from here till ER
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 2:12 PM
$DGX beats Q3 predictions — what’s driving the gains? 🚀 Quest Diagnostics posted a 13% YoY increase in adjusted EPS, beating the Zacks Consensus Estimate by 3.59%, with revenues up 15.2% YoY to $2.82B, surpassing expectations. 📈 Discover the catalysts behind DGX’s growth here 👉 https://www.zacks.com/stock/news/2772997/quest-diagnostics-stock-up-on-q3-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2772997-body-16831&ADID=SYND_STOCKTWITS_TWEET_2_2772997_BODY_16831
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 1:12 PM
$DGX delivers — and the market noticed. 🚀 Q3 earnings and revenue topped expectations, with margins on the rise — a solid combo that’s fueling investor confidence in the stock. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2772997/quest-diagnostics-stock-up-on-q3-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2772997-teaser-16824&ADID=SYND_STOCKTWITS_TWEET_2_2772997_TEASER_16824
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 10:38 AM
Enter: $DGX NOV 21 2025 $195 CALLS Buy in Price: $4.59 - $4.82 Take Profit: $9.78 Stop Bleeding: $4.04 ROI Potential: 113% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 1:21 PM
Enter: $DGX NOV 21 2025 $190 CALLS Buy in Price: $6.50 - $6.90 Take Profit: $10.33 Stop Bleeding: $5.72 ROI Potential: 59% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 20 at 10:11 AM
$DGX SignalEngine: MM Infl (Bearish) (1h + 5m), Algo Vol 49%, Org Vol 51%, Res 4.77, Sup 3.20 Algo Int: Sustained buying momentum reclaiming mid-channel.. watching for clean continuation above range. Momentum Feed: https://premarketanalysis.com/#momentum=DGX
0 · Reply
Small_time_trader
Small_time_trader Oct. 17 at 3:52 PM
$DGX 190 threshold bitch slapped dgx a few weeks ago…let’s see if it holds up better this time. Either way great ride up the last few years
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:53 PM
UBS has updated their rating for Quest Diagnostics ( $DGX ) to Neutral with a price target of 190.
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:27 PM
Mizuho updates rating for Quest Diagnostics ( $DGX ) to Outperform, target set at 190 → 210.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 12:30 AM
Enter: $DGX NOV 21 2025 $190 CALLS Buy in Price: $5.61 - $6.40 Take Profit: $10.55 Stop Bleeding: $4.94 ROI Potential: 88% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply